| Website | svlsa.com |
| Phone | 650-571-8200 |
| Employees | |
| Description | Venture capital Firm |
| Life Sciences Fund V, 6/10 | $523M |
SV Life Sciences is a venture capital adviser and manager that makes selected investments in entrepreneurs and management teams.
SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services. SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.5 billion which primarily invest amounts of between $1m and $40m in North America and Europe, but will consider innovative investments in other regions. Our team of 34 professionals has a diverse, complimentary set of skills and experience that allow us to tailor a team to work with almost any life sciences business.
| Company | Date | Round | Size | Participants |
| CSA Medical | 12/11 | Series B | $20.5M | 4 |
| Catabasis Pharmaceuticals | 12/11 | Series A | $8M | 4 |
| TopiVert | 12/11 | Unattributed | £8M | 2 |
| AcuFocus | 11/11 | Series F | $65M | 5 |
| Rempex Pharmaceuticals | 11/11 | Series B | $67.5M | 5 |
| Imagen Biotech | 10/11 | Series A | $40M | 3 |
| CardioKinetix | 9/11 | Series E | $44M | 4 |
| Affinium Pharmaceuticals | 8/11 | Unattributed | $15M | 3 |
| KalVista Pharmaceuticals | 8/11 | Series A | £8M | 2 |
| Entellus Medical | 8/11 | Series E | $35M | 5 |
| Vantia Therapeutics | 7/11 | Series B | $6.5M | 3 |
| Cyterix Pharmaceuticals | 6/11 | Series A | $9.2M | 2 |
| Delenex Therapeutics | 5/11 | Series A | $19.3M | 6 |
| CardioFocus | 2/11 | Series C | $30.6M | 9 |
| Arsanis | 2/11 | Series A | $10M | 3 |
| PanOptica | 1/11 | Series A | $30M | 2 |
| Sutro Biopharma | 11/10 | Series C | $36.5M | 5 |
| Delenex Therapeutics | 11/10 | Series A | $14M | 4 |
| Convergence Pharmaceuticals | 10/10 | Series A | $35.4M | 3 |
| Good Start Genetics | 9/10 | Series A | $18M | 3 |
| Altura Medical | 6/10 | Series A | $20M | 3 |
| AqueSys | 6/10 | Series C | $35M | 5 |
| Logical Therapeutics | 5/10 | Series C | $16.9M | 3 |
| Catabasis Pharmaceuticals | 4/10 | Series A | $39M | 4 |
| Juvaris BioTherapeutics | 4/10 | Series B | $12.5M | 2 |
| Juvaris BioTherapeutics | 1/10 | Series B | $25M | 2 |
| Adimab | 1/10 | Series D | $8.2M | 5 |
| TransEnterix | 1/10 | Series B | $55M | 6 |
| Ophthotech | 12/09 | Series B | $30M | 4 |
| Oxagen | 11/09 | Series C | $26.7M | 9 |
| Entellus Medical | 11/09 | Series D | $30M | 3 |
| ValenTx | 10/09 | Series B | $20.3M | 6 |
| Lux Biosciences | 10/09 | Series B | $50M | 4 |
| Cadent | 8/09 | Unattributed | $15M | 5 |
| Ocular Therapeutix | 6/09 | Series C | $15M | 3 |
| Sadra Medical | 5/09 | Series C | $30M | 7 |
| Sutro Biopharma | 3/09 | Series B | $15M | 2 |
| NKT Therapeutics | 3/09 | Series A | $8M | 2 |
| LensX Lasers | 3/09 | Series B | $22.4M | 3 |
| ReShape Medical | 2/09 | Series B | $20M | 3 |
| Adimab | 11/08 | Series C | $4M | 4 |
| ESBATech | 8/08 | Series B | $22M | 7 |
| EBR Systems | 6/08 | Series C | $35M | 5 |
| Entellus Medical | 5/08 | Series C | $15M | 3 |
| Sutro Biopharma | 12/07 | Series B | $21M | 2 |
| Fundamental Applied Biology | 12/07 | Series B | $21M | 2 |
| Sutro Biopharma | 10/07 | Unattributed | $305k | 2 |
| Adimab | 9/07 | Series A | $5.9M | 2 |
| ReShape Medical | 8/07 | Series A | $3M | 2 |
| Entellus Medical | 5/07 | Series B | $9M | 2 |
| NeoVista | 12/06 | Series C | $41M | 6 |
| Neurotech | 11/06 | Series B | $35M | 12 |
| Sadra Medical | 10/06 | Series B | $19M | 5 |
| NeoVista | 9/06 | Series B | $26M | 4 |
| ESBATech | 8/06 | Series B | $41M | 7 |
| Entellus Medical | 4/06 | Series A | $3M | 2 |
| Sutro Biopharma | 2006 | Series A | $1M | 1 |
| Mpex Pharmaceuticals | 8/05 | Series B | $32M | 6 |
